Send Inquiry

Request To Call Back

Cizumab Bevacizumab Injection

Name: Cizumab Bevacizumab Injection
Brand: ONCOTRUST
Price: 7197.0 INR
Availability: InStock

Price 7197.0 INR/ Piece

Get a Price/Quote

MOQ : 2 Pieces

Cizumab Bevacizumab Injection Specification

Indication
Metastatic colorectal cancer, lung cancer, kidney cancer, glioblastoma, cervical cancer, ovarian cancer and other solid tumors

Dosage Form
Injection

Salt Composition
Bevacizumab 400 mg/16 ml

Feature
Monoclonal antibody; inhibits angiogenesis by targeting VEGF

Ingredients
Bevacizumab

Application
Anti-cancer therapy via intravenous infusion

Temperature Needed For Fermentation
2 C to 8 C Celsius (oC)

Physical Color/Texture
Clear to slightly opalescent, colorless to pale brownish-yellow solution

Fermentation Smell
Odorless

Storage Instructions
Store at 2C-8C. Do not freeze. Protect from light.

Shelf Life
30 months

Marketed By
Hetero Healthcare

Contraindications
Hypersensitivity to bevacizumab or any excipients

Diluent Used
0.9% Sodium Chloride Injection (do not use dextrose)

Approved Use
For use in adults only

Pack Size
Single use vial of 16 ml

Prescription Status
Prescription only

Concentration
25 mg/ml

Molecular Type
Recombinant humanized monoclonal antibody

Reconstitution
Not required, provided as ready-to-use solution

Route of Administration
Intravenous infusion after dilution

Packaging Type
Glass vial with flip-off seal

Cizumab Bevacizumab Injection Trade Information

Minimum Order Quantity
2 Pieces

Delivery Time
24 Hours

About Cizumab Bevacizumab Injection

Cizumab Bevacizumab Injection is a high-quality, targeted monoclonal antibody formulation used in the treatment of various types of cancers. It works by inhibiting vascular endothelial growth factor (VEGF), thereby preventing the formation of new blood vessels that tumors need to grow and spread.

This injection is widely prescribed as part of combination therapy for conditions such as metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, and certain gynecological cancers. Manufactured under stringent quality standards, Cizumab ensures safety, efficacy, and consistent performance.

Key Features:

Contains Bevacizumab as the active ingredient
Anti-angiogenic action to restrict tumor growth
Used in multiple oncology indications
High purity and clinically proven formulation
Manufactured in WHO-GMP compliant facilities

Packaging Details:

Available in sterile vial form
Different strengths available as per requirement
Secure, tamper-proof packaging

Usage:

Administered intravenously under the supervision of a qualified healthcare professional
Dosage and duration depend on the patient's condition and medical history

Storage:

Store in a refrigerator (2C to 8C)
Do not freeze

Ready-to-Use, Highly Targeted Anti-Cancer Solution

Cizumab Bevacizumab Injection is uniquely designed as a single-use vial with a pre-prepared solution requiring no reconstitution. Its recombinant monoclonal antibody formulation specifically inhibits the growth of new blood vessels in tumors, making it effective against various cancers when prescribed by your oncologist.

Safe and Convenient Administration

Packaged in a 16 ml glass vial with a flip-off seal, Cizumab is easy to handle and intended for intravenous infusion after dilution with 0.9% sodium chloride. It must not be diluted with dextrose solutions and should only be administered by healthcare professionals.

Storage and Shelf Life Assurance

To guarantee potency and safety, store Cizumab at 2C to 8C; avoid freezing and protect from light. The product retains its efficacy for up to 30 months when stored properly.

FAQ's of Cizumab Bevacizumab Injection:

Q: How should Cizumab Bevacizumab Injection be administered?

A: Cizumab must be administered via intravenous infusion after dilution with 0.9% sodium chloride. It is not suitable for dextrose dilution, and the procedure should only be performed by qualified healthcare professionals.

Q: What is the main benefit of using Cizumab for cancer therapy?

A: Cizumab works by inhibiting the formation of blood vessels (angiogenesis) in tumors, which helps to restrict tumor growth and spread, offering a targeted therapeutic approach for several types of solid tumors.

Q: When is Cizumab indicated for use?

A: Cizumab is prescribed in the treatment of metastatic colorectal cancer, non-small cell lung cancer, kidney cancer, glioblastoma, cervical cancer, ovarian cancer, and other solid tumors in adults.

Q: Where should Cizumab vials be stored?

A: Cizumab vials must be stored between 2C and 8C in a refrigerator; they should not be frozen and must be protected from exposure to light.

Q: What process must be followed before administering Cizumab?

A: No reconstitution is required. The solution is provided ready-to-use. Before infusion, it should be diluted only with 0.9% sodium chloride, and administration must occur under medical supervision.